Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Chiome Bioscience Inc. (4583.T)
Tokyo, JP
Chiome Bioscience Inc. engages in the research and development of drug discovery technology platforms worldwide. It operates in two segments, Drug Discovery Business and Drug Discovery Support Business. The company offers ADLib System, a technology for generating monoclonal antibodies which is used to generate antibodies for drug discovery research; and Human ADLib System, which converts chicken antibody genes to humanized antibodies. It also provides protein expression and purification services; stable cell line development services for recombinant protein and antibody production; and antibody generation services using the ADLib system. In addition, the company's product pipeline under Phase 1 trial comprises ADCT-701, an anti-dlk1 antibody for treating liver cancer; CBA-1205, an afucosylated anti-dlk1 antibody for liver cancer, lung cancer, and neuroblastoma; and CBA-1535, an anti 5T4/WAIF1 antibody for malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, and triple negative breast cancer (TNBC). Further, its product pipeline under preclinical study includes PCDC, an anti- CDCP1 antibody for lung, colorectal, pancreatic, breast, and ovarian tumors; PTRY, an antibody 5T4/CD3/PD-L1 for treating malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, and TNBC; BMAA, an anti-semphorin3a antibody for treating renal and other diseases; LIV-2008/2008b, an anti-TROP-2 antibody for the treatment of TNBC, lung cancer, and colorectal cancer; PFKR, an anti-CX3CR1 antibody for secondary progressive multiple sclerosis; and PXLR, an anti-CXCL1/2/3/5 antibody for the treatment of gastric, breast, and ovarian tumors. Chiome Bioscience Inc. was incorporated in 2005 and is headquartered in Tokyo, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -5.26% | -12.62% | -21.74% | -26.83% | -15.89% | -39.19% | -57.55% | -58.33% | -86.67% | -69.36% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-24.0% Q1'26: +6.1% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+17.5% Q1'26: +16.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-158.9% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-165.1% Q1'26: -157.9% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-548.2% Q1'26: -361.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+16.7% Q1'26: +4.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.27× Q1'26: -0.09× (vs Q1'25)
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
280.11M
est: 250.00M (+12.0%)
|
252.22M
est: 250.00M (+0.9%)
|
259.89M
est: 200.00M (+29.9%)
|
212.85M
est: 200.00M (+6.4%)
|
447.58M
est: 430.00M (+4.1%)
|
480.85M
est: 600.00M (-19.9%)
|
712.93M
est: 730.00M (-2.3%)
|
630.82M
est: 750.00M (-15.9%)
|
682.46M
est: 800.00M (-14.7%)
|
780.81M
est: 1.25B (-37.5%)
|
| EBITDA |
-1.17B
est: -250.00M (-367.0%)
|
-929.26M
est: -250.00M (-271.7%)
|
-877.28M
est: -200.00M (-338.6%)
|
-1.53B
est: -200.00M (-666.1%)
|
-1.40B
est: -430.00M (-224.9%)
|
-1.28B
est: -600.00M (-113.3%)
|
-1.33B
est: -730.00M (-82.4%)
|
-1.26B
est: -750.00M (-67.6%)
|
-1.20B
est: -800.00M (-50.5%)
|
-1.03B
est: -1.25B (+17.6%)
|
| EBIT |
-1.27B
est: -250.00M (-408.0%)
|
-1.04B
est: -250.00M (-316.9%)
|
-887.87M
est: -200.00M (-343.9%)
|
-1.54B
est: -200.00M (-669.6%)
|
-1.40B
est: -430.00M (-226.0%)
|
-1.28B
est: -600.00M (-113.9%)
|
-1.33B
est: -730.00M (-82.8%)
|
-1.26B
est: -750.00M (-67.8%)
|
-1.21B
est: -800.00M (-50.6%)
|
-1.03B
est: -1.25B (+17.5%)
|
| Net Income |
-1.28B
est: -3.17B (+59.5%)
|
-1.49B
est: -2.86B (+47.8%)
|
-882.57M
est: -2.01B (+56.1%)
|
-1.53B
est: -2.89B (+47.0%)
|
-1.40B
est: -2.70B (+47.9%)
|
-1.29B
est: -2.25B (+42.4%)
|
-1.48B
est: -1.61B (+7.9%)
|
-1.24B
est: -1.76B (+29.3%)
|
-1.22B
est: -1.71B (+28.7%)
|
-1.02B
est: -1.17B (+12.6%)
|
| SGA |
567.06M
est: 181.48M (+212.5%)
|
514.63M
est: 181.48M (+183.6%)
|
469.90M
est: 145.18M (+223.7%)
|
420.06M
est: 145.18M (+189.3%)
|
387.52M
est: 312.14M (+24.1%)
|
372.31M
est: 435.54M (-14.5%)
|
444.59M
est: 529.91M (-16.1%)
|
471.90M
est: 544.43M (-13.3%)
|
551.86M
est: 580.72M (-5.0%)
|
526.98M
est: 949.29M (-44.5%)
|
| EPS |
-58.29
est: -54.40 (-7.2%)
|
-65.91
est: -49.10 (-34.2%)
|
-33.48
est: -34.50 (+3.0%)
|
-57.26
est: -49.70 (-15.2%)
|
-44.61
est: -46.30 (+3.7%)
|
-36.06
est: -38.60 (+6.6%)
|
-36.74
est: -27.60 (-33.1%)
|
-28.26
est: -30.20 (+6.4%)
|
-24.62
est: -29.40 (+16.3%)
|
-17.54
est: -17.20 (-2.0%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Arihiko Bijohira | Executive VP, COO, Chief Strategy Officer & Director | — | male |
| Masamichi Koike | President, Chief Executive Officer & Executive Director | — | — |
| Teruyo Taoka | Head of Development Division & Director | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4583.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
